CSL Vifor and Travere Welcome KDIGO 2025 Guidelines for IgA Nephropathy, Highlight FILSPARI®

St. Gallen, Switzerland & San Diego, CA – CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced their support for the newly published Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the management of IgA Nephropathy (IgAN) and IgA Vasculitis.

The updated recommendations redefine treatment goals and approaches for IgAN, with proteinuria remission (<0.5 g/day, ideally <0.3 g/day) and slowing eGFR decline set as key targets.

FILSPARI® Recognized in Updated Guidelines

• FILSPARI® (sparsentan), the first dual endothelin angiotensin receptor antagonist (DEARA), is highlighted as a potential first-line therapy for managing IgAN-driven nephron loss.
• FILSPARI is the only therapy with proven efficacy over optimized RASi in a Phase 3 head-to-head trial (PROTECT).
• The PROTECT trial enrolled more patients than all prior RASi IgAN studies combined.

Expert Perspectives

“The updated KDIGO guidance provides greater clarity and confidence for clinicians, ultimately aiming to improve long-term kidney outcomes.”

• Prof. Jürgen Floege, University Hospital RWTH Aachen.

“Inclusion of FILSPARI underscores its clinical benefit in reducing proteinuria and slowing kidney function decline.”

• Dr. Achim Obergfell, Global Medical Head Nephrology, CSL Vifor.

“This milestone reflects advances in understanding IgAN and validates FILSPARI as a foundational treatment.”

• Dr. Jula Inrig, CMO, Travere Therapeutics.

About the PROTECT Study

• Design: Phase 3, global, randomized, head-to-head trial of FILSPARI (400 mg) vs. irbesartan (300 mg) in 404 IgAN patients.
• Primary results (Week 36): FILSPARI achieved a 49.8% mean reduction in proteinuria vs. 15.1% with irbesartan (p<0.0001).
• Final results (Week 110): FILSPARI slowed kidney function decline compared with irbesartan.
• Safety: Adverse events were balanced between arms; dizziness and hypotension more frequent with FILSPARI.

About IgA Nephropathy

• IgAN is a rare progressive kidney disease and a leading cause of kidney failure worldwide.
• Estimated to affect >250,000 people across licensed territories.
• Symptoms include hematuria, proteinuria, high blood pressure, and progressive loss of kidney function.

About FILSPARI® (sparsentan)

• Class: Non-immunosuppressive DEARA with dual selectivity for ETAR and AT1R.
• Status: Approved for IgAN in the U.S. and Europe; launched in the U.S., Germany, Austria, Switzerland, Luxembourg, and the UK.
• Designation: Orphan Drug status in U.S., EU, and UK.
• Rights: Developed by Travere; CSL Vifor holds exclusive commercialization rights in Europe, Australia, New Zealand, and select territories.

About CSL Vifor

Global partner of choice in iron deficiency and nephrology, headquartered in St. Gallen, Switzerland, with 29,000+ employees worldwide. More: CSL.com

About Travere Therapeutics

Biopharma company dedicated to rare diseases, headquartered in San Diego, CA. More: travere.co

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!